Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 1.00 |
| ▸ | MMP9 | P14780 | 12/20 | 1.00 |
| ▸ | MMP3 | P08254 | 11/20 | 1.00 |
| ▸ | MMP13 | P45452 | 11/20 | 1.00 |
| ▸ | MMP1 | P03956 | 10/20 | 1.00 |
| ▸ | MMP7 | P09237 | 10/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 5/20 | 0.78 |
| ▸ | MMP14 | P50281 | 1/20 | 0.74 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618803 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL32691806 | 0.88 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1750956 | 0.88 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4653257 | 0.88 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1655901 | 0.87 | ADAMTS4 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8283899 | 0.87 | ADAMTS4 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7870619 | 0.87 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7870625 | 0.87 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1110930 | 0.86 | MMP2 (0.75) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL3607214 | 0.86 | MMP2 (0.75) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0901466-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-03-17 | — | — | EP | claimed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997044315-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | MMP2 1658/4885MMP9 2591/4885MMP3 2192/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | MMP2 2127/4885MMP9 757/4885MMP3 2397/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | MMP2 2619/4885MMP9 2764/4885MMP3 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.